文献速递艾滋病与性传播感染结核与非结核分枝杆菌

SHINE试验中接受非严重结核病治疗的HIV感染儿童的临床结局

Clinical Outcomes in Children With Human Immunodeficiency Virus Treated for Nonsevere Tuberculosis in the SHINE Trial.
PubMed 文献 · Clin Infect Dis · 2024-01-01

SHINE试验纳入1204例涂片阴性非严重结核病儿童,其中127例(11%)为HIV感染儿童(CWH),随机接受4个月或6个月抗结核治疗并随访72周。CWH的结核复发/再发、死亡、住院及≥3级不良事件按HIV状态评估,CWH中45%和61%在24周和48周病毒载量<1000拷贝/mL。结论:CWH中4个月与6个月治疗结核结局无差异证据,但CWH死亡和住院率高于无HIV儿童。

要点

  • CWH较无HIV儿童更易住院(调整OR 2.4;95%CI 1.3-4.6)和死亡(调整HR 2.6;95%CI 1.2-5.8)。
  • HIV状态、年龄<3岁、营养不良和血红蛋白<7 g/dL独立预测死亡。
  • 按HIV状态分层,4个月与6个月抗结核治疗对结核结局的效应无差异(交互P=0.42)。

核心结论

  • 在非严重结核病CWH中,未发现4个月与6个月治疗结核结局存在差异的证据。
  • 无论抗结核治疗时长如何,CWH的死亡率和住院率均高于无HIV儿童。

研究设计与样本

  • SHINE为随机试验,纳入年龄<16岁、涂片阴性、非严重结核病儿童,随机接受4个月或6个月抗结核治疗并随访72周。
  • 共纳入1204例儿童,其中127例(11%)为CWH。

主要发现

  • CWH与无HIV儿童年龄相似(中位3.6岁;IQR 1.2-10.3 vs 3.5岁;IQR 1.5-6.9;P=0.07)。
  • CWH较无HIV儿童更体重不足(年龄别体重z评分-2.3;IQR -3.3至-0.8 vs -1.0;IQR -1.8至-0.2;P<0.01)和贫血(血红蛋白9.5 g/dL;IQR 8.7-10.9 vs 11.5 g/dL;IQR 10.4-12.3;P<0.01)。
  • 68例(54%)CWH为ART初治;基线中位CD4计数719 cells/mm3(241-1134),CD4%为16%(10-26)。
  • CWH更易住院(调整OR 2.4;95%CI 1.3-4.6)和死亡(调整HR 2.6;95%CI 1.2-5.8)。
  • 年龄<3岁(调整HR 6.3;95%CI 1.5-27.3)、营养不良(调整HR 6.2;95%CI 2.4-15.9)和血红蛋白<7 g/dL(调整HR 3.8;95%CI 1.3-11.5)独立预测死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children with human immunodeficiency virus (HIV, CWH) are at high risk of tuberculosis (TB) and face poor outcomes, despite antiretroviral therapy (ART). We evaluated outcomes in CWH and children not living with HIV treated for nonsevere TB in the SHINE trial. METHODS: SHINE was a randomized trial that enrolled children aged <16 years with smear-negative, nonsevere TB who were randomized to receive 4 versus 6 months of TB treatment and followed for 72 weeks. We assessed TB relapse/recurrence, mortality, hospitalizations, grade ≥3 adverse events by HIV status, and HIV virological suppression in CWH. RESULTS: Of 1204 children enrolled, 127 (11%) were CWH, of similar age (median, 3.6 years; interquartile range, 1.2, 10.3 versus 3.5 years; 1.5, 6.9; P = .07) but more underweight (weight-for-age z score, -2.3; (3.3, -0.8 versus -1.0; -1.8, -0.2; P < .01) and anemic (hemoglobin, 9.5 g/dL; 8.7, 10.9 versus 11.5 g/dL; 10.4, 12.3; P < .01) compared with children without HIV. A total of 68 (54%) CWH were ART-naive; baseline median CD4 count was 719 cells/mm3 (241-1134), and CD4% was 16% (10-26). CWH were more likely to be hospitalized (adjusted odds ratio, 2.4; 1.3-4.6) and to die (adjusted hazard ratio [aHR], 2.6; 95% confidence interval [CI], 1.2 to 5.8). HIV status, age <3 years (aHR, 6.3; 1.5, 27.3), malnutrition (aHR, 6.2; 2.4, 15.9), and hemoglobin <7 g/dL (aHR, 3.8; 1.3,11.5) independently predicted mortality. Among children with available viral load (VL), 45% and 61% CWH had VL <1000 copies/mL at weeks 24 and 48, respectively. There was no difference in the effect of randomized treatment duration (4 versus 6 months) on TB treatment outcomes by HIV status (P for interaction = 0.42). CONCLUSIONS: We found no evidence of a difference in TB outcomes between 4 and 6 months of treatment for CWH treated for nonsevere TB. Irrespective of TB treatment duration, CWH had higher rates of mortality and hospitalization than their counterparts without HIV. Clinical Trials Registration. ISRCTN63579542.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chabala C, Wobudeya E, van der Zalm MM, et al. Clinical Outcomes in Children With Human Immunodeficiency Virus Treated for Nonsevere Tuberculosis in the SHINE Trial. Clin Infect Dis. 2024. PMID: 38592950. doi:10.1093/cid/ciae193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。